# US 2023/0407270 A1 · Polypeptide compositions and methods for use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407270 A1
- Document ID: US20230407270A1
- Status: Published application
- Kind: A1
- Application number: 18/251,117
- Filed: 2021-11-02
- Published: 2023-12-21
- Earliest claimed: 2020-11-02
- Applicants: Totus Medicines Inc.
- Inventors: Neil Sonin DHAWAN; James Abellera BLAIR
- Web page: https://patentgrep.com/patent/US20230407270A1

## CPC

- C12N 9/0069: {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- C12Q 1/66: involving luciferase
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- C12Y 113/12013: Oplophorus-luciferin 2-monooxygenase (1.13.12.13)
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure generally relates to synthetic bioluminescent proteins such as synthetic luciferase polypeptides. Methods of making and using the proteins are also provided herein.

## Claims

### Claim 1

A polypeptide comprising an amino acid sequence I:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQX1IVLSGENG LX2IDIHVIIPYEGLSGDQMGQIEX3IFX4VVYPVDDHHFKVILHYGTLVIDGVTPN MIDYFGRPYEGIAVFDGX5X6ITVTGTLWNGNX7IIDERLINPDGSLLFRVTINGVT GWRLX8ERILA, wherein X1, X2, X3, X4, X5, X6, and X7 are independently R or K; X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V; and optionally comprising an amino acid sequence X9ERILA attached to rightmost A residue, wherein X9 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein X1 is R.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein X1 is K.

### Claim 4 (depends on 1, 2, 3)

The polypeptide of any one of claims 1-3, wherein X2 is R.

### Claim 5 (depends on 1, 2, 3)

The polypeptide of any one of claims 1-3, wherein X2 is K.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The polypeptide of any one of claims 1-5, wherein X3 is R.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The polypeptide of any one of claims 1-5, wherein X3 is K.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The polypeptide of any one of claims 1-7, wherein X4 is R.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The polypeptide of any one of claims 1-7, wherein X4 is K.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The polypeptide of any one of claims 1-9, wherein X5 and X6 are both R.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The polypeptide of any one of claims 1-9, wherein X5 and X6 are both K.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The polypeptide of any one of claims 1-11, wherein X7 is R.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The polypeptide of any one of claims 1-11, wherein X7 is K.

### Claim 14 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence II:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGL KIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLLFRVTINGVTGWRL X8ERILA, wherein X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 15 (depends on 14)

The polypeptide of claim 14, wherein said polypeptide is selected from the group consisting of SEQ ID NOs 1 to 19.

### Claim 16 (depends on 15)

The polypeptide of claim 15, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.

### Claim 17 (depends on 15, 16)

The polypeptide of claims 15 or 16, wherein said polypeptide is selected from the group consisting of SEQ ID NO:8, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO:19.

### Claim 18 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence III:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGL RIDIHVIIPYEGLSGDQMGQIERIFRVVYPVDDHHFRVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGKKITVTGTLWNGNRIIDERLINPDGSLLFRVTINGVTGWRL X8ERILA, wherein X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 19 (depends on 18)

The polypeptide of claim 18, wherein said polypeptide is selected from the group consisting of SEQ ID NOs 20 to 38.

### Claim 20 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence IV:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGL RIDIHVIIPYEGLSGDQMGQIERIFRVVYPVDDHHFKVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGKKITVTGTLWNGNRIIDERLINPDGSLLFRVTINGVTGWRL X8ERILA, wherein X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 21 (depends on 20)

The polypeptide of claim 20 wherein said polypeptide is selected from the group consisting of SEQ ID NOs 39 to 57.

### Claim 22 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence V:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGL RIDIHVIIPYEGLSGDQMGQIERIFRVVYPVDDHHFKVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGRRITVTGTLWNGNRIIDERLINPDGSLLFRVTINGVTGWRL AERILAX9ERILA, wherein X9 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 23 (depends on 22)

The polypeptide of claim 22 wherein said polypeptide is selected from the group consisting of SEQ ID NOs 58 to 76.

### Claim 24 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence VI:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQKIVLSGENGL KIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLLFRVTINGVTGWRL X8ERILA, wherein X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 25 (depends on 24)

The polypeptide of claim 24 wherein said polypeptide is selected from the group consisting of SEQ ID NOs 77 to 95.

### Claim 26 (depends on 1)

The polypeptide of claim 1, comprising an amino acid sequence VII:
MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQKIVLSGENGL RIDIHVIIPYEGLSGDQMGQIERIFRVVYPVDDHHFKVILHYGTLVIDGVTPNMID YFGRPYEGIAVFDGRRITVTGTLWNGNRIIDERLINPDGSLLFRVTINGVTGWRL X8ERILA, wherein X8 is selected from the group consisting of A, R, N, D, E, Q, G, H, I, L, K, M, F, P, S, T, W, Y and V.

### Claim 27 (depends on 26)

The polypeptide of claim 26 wherein said polypeptide is selected from the group consisting of SEQ ID NOs 96 to 114.

### Claim 28

A polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs 1 to 114.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A polynucleotide encoding the polypeptide selected from any one of the claims 1 to 28.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A kit for luminescence assays comprising the polypeptide of any one of claims 1-28.

### Claim 31 (depends on 30)

The kit of claim 30, further comprise a substrate for the polypeptide.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the substrate is selected from the group consisting of furimazine, coelenterazine, bisdeoxycoelenterazine, coelenterazine 400a, coelenterazine cp, coelenterazine f, coelenterazine fcp, coelenterazine h, coelenterazine hcp, coelenterazine i, coelenterazine ip, methyl coelenterazine, coelenterazine n, hydrofurimazine and fluorofurimazine.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of producing luminescence comprising contacting the polypeptide of any one of claims 1-28 with a substrate for the polypeptide.

### Claim 34 (depends on 33)

The method of claim 33, wherein the substrate is selected from the group consisting of furimazine, coelenterazine, bisdeoxycoelenterazine, coelenterazine 400a, coelenterazine cp, coelenterazine f, coelenterazine fcp, coelenterazine h, coelenterazine hcp, coelenterazine i, coelenterazine ip, methyl coelenterazine, coelenterazine n, hydrofurimazine and fluorofurimazine.
